ENTITY – Page 6

InflaRx Halts Rare Skin Disease Study for Vilobelimab After Futility Signal

2 weeks ago talkbio0Tagged Clinical Trials, COVID19 (disease), Drug Development, Futility, INF904, InflaRx, Pyoderma Gangrenosum, vilobelimab

InflaRx; vilobelimab; pyoderma gangrenosum; futility; clinical trial; COVID-19; drug development; INF904

Recent Developments in NLP and Generative AI for Life Sciences and Precision Medicine (2025)

2 weeks ago talkbio0Tagged Biological Science Disciplines, Drug Discovery, Generative AI, Health care facility, language models, multimodal AI, NINL gene, Pharmacovigilance, Precision Medicine, quality management

NLP; Generative AI; life sciences; precision medicine; healthcare; large language models; multimodal AI; quality management; drug discovery; pharmacovigilance

Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M

2 weeks ago talkbio0Tagged Angelini Pharma, Blackstone Life Sciences, Grin, Neurodevelopmental Disorders, pharma partnerships, radiprodil, Series D financing, Syndeio

Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships

Eli Lilly Acquires SiteOne for Up to $1B to Expand Non-Opioid Pain Pipeline

2 weeks ago talkbio0Tagged Acquisition, Chronic pain, Drug Industry, eli lilly, Nav1.8 inhibitor, neuroscience pipeline, non-opioid pain treatment, SiteOne Therapeutics, STC-004

Eli Lilly; SiteOne Therapeutics; non-opioid pain treatment; STC-004; acquisition; Nav1.8 inhibitor; chronic pain; neuroscience pipeline; Vertex; pharmaceutical industry

Trump Taps Dr. Oz as Lead Negotiator for ‘Most Favored Nation’ Drug Pricing Policy

2 weeks ago talkbio0Tagged Dr., Drug Costs, drug price, Health Policy, Myasthenic Syndromes, Congenital, Nation, ounce, pharmaceutical negotiations, Transplant Registry Unified Management Program

Trump; Dr. Mehmet Oz; Most Favored Nation; drug pricing; CMS; pharmaceutical negotiations; healthcare policy; drug costs

Sernova Chair Resigns After Insider Trading Indictment Tied to Novartis-Chinook Deal

2 weeks ago talkbio0Tagged biotherapeutics, DOJ, indictment, insider trading, News [Publication Type], Novartis-Chinook acquisition, resignation, Ross Haghighat, securities fraud, Sernova

Sernova Biotherapeutics; insider trading; resignation; Ross Haghighat; Novartis-Chinook acquisition; securities fraud; biotech news; DOJ indictment

Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold

2 weeks ago talkbio0Tagged acute systemic infection, Adverse event, Capillary Leak Syndrome, gene therapy, Glycogen Storage Disease Type IIb, Patient Death, Rocket, RP-A501, Study on Hold, United States Food and Drug Administration

Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event

Prothena Halts Drug and Plans Major Layoffs After Second Rare Disease Trial Failure

2 weeks ago talkbio0Tagged AL, birtamimab, business options, drug failure, layoffs, Phase 3 Clinical Trials, Primary amyloidosis, Prothena, spending

Prothena; birtamimab; AL amyloidosis; Phase III trial; drug failure; layoffs; biotech; spending cuts; business options

Boundless Bio Lays Off 33% of Staff Following Stumble of Lead Program

2 weeks ago talkbio0Tagged BBI-355, BBI-825, Bio, Boundless, CHEK1 protein, human, Clinical Trials, Combined Modality Therapy, Inhibitor, layoffs, pipeline restructuring, ribonucleoside-diphosphate reductase activity, Solid Neoplasm

Boundless Bio; layoffs; biotech; clinical trial; BBI-355; BBI-825; RNR inhibitor; CHK1 inhibitor; combination therapy; solid tumors; pipeline restructuring

GlycoEra Raises $130M to Advance Protein Degraders Toward Clinic

2 weeks ago talkbio0Tagged Autoantibodies, Autoimmune Diseases, Clinical Trials, Funding, GE8820, GlycoEra, Holdings, Immunoglobulin IgG4, Precision Immunology, protein degraders

GlycoEra; protein degraders; $130 million funding; autoimmune diseases; GE8820; IgG4 autoantibodies; Novo Holdings; clinical trial; precision immunology